AI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trial
Nature Medicine, Published online: 24 July 2026; doi:10.1038/s41591-026-04545-w
Retina4IRD, an AI-based clinician decision support system, enhances inherited retinal disease diagnosis through multimodal imaging and clinical data integration, achieving 88.5% accuracy in a randomized clinical trial.
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
Nature Medicine, Published online: 24 July 2026; doi:10.1038/s41591-026-04496-2
In the LITMUS study, serum biomarkers outperformed imaging for identifying patients at risk of MASH, whereas elastography was superior for staging advanced fibrosis and cirrhosis.
A new, separate outbreak of the diarrhea-causing parasite
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Yesterday, my friend who lives in the Bay Area told me that I should be asking people about their peptide “stack,” which is where someone takes multiple peptides for presumably greater health benefit.
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
Amid rising concern over efforts to contain HIV, Merck has reached voluntary licensing deals with seven companies to make generic versions of an experimental, once-a-month prevention pill in 129 low- and middle-income countries.
The agreements will allow the manufacturers — three of which are based in Africa and four in India — to sell generic versions to both public and private buyers, which is designed to ensure the medicine becomes available to the widest possible population. Moreover, the deals are royalty free, which makes it easier for the generic companies to predict costs.
The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production and the necessary steps to receive regulatory approvals around the world.
Drug Candidate Combats Age-Related Muscle Loss
Researchers in Japan have identified a compound that could help muscles stay strong as we age. Preclinical results published today in Scientific Reports uncover a promising new approach to treat conditions causing muscle loss and may help people preserve independence and quality of life in their later years.
Skeletal muscle is essential for movement, accounting for approximately 40% of an adult’s total body weight. Yet it is also one of the first tissues to decline with age, progressively leading to weakness, scarring, fat accumulation, and loss of fast-twitch muscle fibers.
The study focused on hepatocyte growth factor (HGF), a molecule that plays a crucial role in activating the repair of muscle fibers. In healthy muscle, this molecule is present in the tissue surrounding muscle fibers. When the muscle is injured or stimulated through exercise, HGF is released and binds to c-met receptors on stem cells within the skeletal muscle, known as satellite cells. This activates the satellite cells and enables them to proliferate and differentiate to repair muscle fibers.
Aging can interfere with this process, making it a key driver of age-related muscle wasting. In an earlier study, the same team found that aging causes HGF to undergo nitration, a chemical modification that prevents it from binding to c-met receptors.
“HGF is not necessarily missing as we age,” said Ryuichi Tatsumi, PhD, professor at Kyushu University. “Rather, it can be chemically altered after it is made. That led us to wonder whether a compound with strong antioxidant capacity might protect HGF, either by preventing nitration or by compensating for the functional loss it causes.”
Tatsumi’s team then identified two compounds with strong antioxidant activity that could potentially interfere with HGF nitration: glutathione trisulfide (GSSSG) and lipoic acid trisulfide (LASSS). Both belong to a drug class known as trisulfides that has been gaining attention in preclinical research for their protective and anti-inflammatory properties across a wide range of indications.
While both drugs were able to suppress HGF nitration, only LASSS restored its ability to bind to c-met receptors. In fact, the drug candidate more than doubled HGF’s binding affinity while simultaneously preventing nitration.
“This exceeded our expectations,” said Tatsumi. “We knew trisulfides had diverse biological functions, but we never expected that simply mixing HGF with LASSS would produce such a striking effect. What this tells us is that LASSS does more than simply neutralize reactive molecules. It may interact directly with HGF and induce a subtle structural change, creating an enhanced ‘Super HGF’ form that binds c-met more strongly and resists nitration.”
The researchers then tested these effects in a mouse model of muscle atrophy. Compared to untreated animals, mice receiving LASSS showed a significant reduction in HGF nitration. Although further preclinical studies are needed before this approach can be tested in humans, these early findings point toward a promising strategy to preserve the muscle’s natural regenerative capacity and support healthy aging.
The post Drug Candidate Combats Age-Related Muscle Loss appeared first on Inside Precision Medicine.
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
Amid debates over whether the political influence of the Make America Healthy Again movement is on the wane, a new bill advanced in the Senate on Wednesday shows that concerns over ultra-processed food continue to upend the usual partisan stances in Washington.
The bill, which would ban junk food advertisements targeted to children and require the Food and Drug Administration to put strong warning labels on ultra-processed foods high in sugar, salt, and saturated fat, was proposed by Sen. Bernie Sanders (I-Vt.).
STAT+: White House offers its science blueprint: More AI, less life sciences
For 18 months, the Trump administration has been accused by science advocates of shredding a social contract between academic researchers and the federal government that made the United States the world’s most powerful engine of discovery. Now it’s proposing a way to rebuild American science.
Taking inspiration from “Science — The Endless Frontier,” a 1945 manifesto that became the blueprint for the rise of American research universities, Trump’s science adviser, Michael Kratsios, this week put forth his version of such a report. Called “Science: A New Golden Age” and drafted by the White House Office of Science and Technology Policy, it calls for shifting hundreds of billions of research dollars from universities to industry, primarily tech and artificial intelligence companies.
The report acknowledges problems scientists have long attempted to grapple with, but advocates and scientists expressed concern that the report’s espoused goal of improving science is being undermined by other administration actions, chiefly the grievances expressed by President Trump and his aides against immigration, universities, and programs that they deem as promoting diversity, equity, and inclusion.
Opinion: The U.S. pharmaceutical supply chain problem is not about China
In 2025, there were 216 active drug shortages in the U.S., impacting Americans’ access to lifesaving medications. The resilience of our pharmaceuticals supply chains has been increasingly framed as a national security issue, including by the White House — and rightly so, as Covid-19 magnified the massive costs of a health system ill-equipped to care for its population.
But this national security framing has heavily skewed toward a U.S.-China competition lens, distracting from the real root causes of our pharmaceuticals supply chain vulnerabilities: inadequate regulation of an industry that tends to prioritize profit over America’s health.
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
Scientists at the Salk Institute and the Arc Institute, along with their collaborators, unveiled the first body-wide single-cell atlas of two major epigenetic systems: three-dimensional genome folding and DNA methylation, measured simultaneously in the same cells.
The atlas spans 86,689 cells from 16 human tissues, revealing 35 major cell types and 206 subtypes, and is freely available online. The work is part of the National Institutes of Health’s 4D Nucleome (NIH 4DN) program, which aims to understand how the genome is organized in space and time to regulate gene expression in health and disease.
Because the two epigenetic layers were measured together, the researchers could compare what each layer says about a cell’s identity. And while often the two pictures agree, they found that sometimes they do not.
The Salk paper “Human body single-cell atlas of 3D genome organization and DNA methylation” was published alongside five other NIH 4DN papers in Science, and three others in Science Advances.
The Human Genome Project, completed in 2003, produced a linear read of the three billion DNA letters in the human body. But the letters alone don’t explain how a single genome produces hundreds of different cell types. That information lives in the epigenome in the form of chemical modifications and structural folds layered on top of the DNA sequence, where they can switch genes “on” and “off” in patterns specific to each cell type.
![Caption: Salk scientists Jingtian Zhou (left), Jesse Dixon (center), and Joseph Ecker (right) profiled 86,689 cells across 16 human tissues, linking cell-type-specific epigenetic features to disease risk and revealing that a cell’s 3D genome and DNA methylation don’t always tell the same story. [Salk Institute]](https://www.genengnews.com/wp-content/uploads/2026/07/260723-pr-ecker-dixon-authors-232x300.jpg)
Two of the most consequential epigenetic features are 1) DNA methylation, where small chemical groups called methyl groups are attached to specific DNA bases, and 2) 3D genome organization, where intricate loops, folds, and compartments bring distant stretches of DNA into contact. Both influence gene expression, but they had never been measured together in single cells across the human body.
“There has been an appreciation for trying to understand, at the individual cell level, how the genome is organized, so that we can get a better idea of how genetic variants impact disease,” said co-corresponding author Joseph Ecker, PhD, a professor and Salk International Council Chair in Genetics at Salk and a Howard Hughes Medical Institute investigator. “Some cell types may be more vulnerable than others to genetic variants, because the genome is organized differently in different cell types—and whether a variant matters can depend on that organization.”
Why is noncoding DNA relevant in disease?
Most disease-associated genetic variants fall in the noncoding regions of the genome. That has made it difficult to figure out how a variant contributes to disease, which cell type it acts in, and what gene it ultimately affects.
The new atlas identifies more than 1.36 million differentially methylated regions and 283,606 differential chromatin loops across the human body’s cell types, using tissues from the heart, brain, lungs, stomach, skin, and more. When the researchers overlaid genetic variants known to raise disease risk, specific pairings emerged like variants for blood-glucose regulation concentrated in endocrine cells, atrial fibrillation variants in heart muscle cells, balding variants in skin fibroblasts, and bipolar disorder and schizophrenia variants in excitatory and inhibitory neurons.
“A lot of the genetic variation that predisposes someone to disease is in noncoding parts of the genome,” said co-corresponding author Jesse Dixon, MD, PhD, associate professor and Helen McLoraine Developmental Chair at Salk. “By adding in the 3D genome aspect, we can potentially bridge that gap—connecting noncoding variations with the genes they affect in specific cells and tissues.”

What happens when two epigenetic lenses disagree?
One of the study’s most surprising findings is that DNA methylation and 3D genome structure don’t always tell the same story about a cell. In skeletal muscle, the team found fibers that look like mature, differentiated muscle cells by their 3D genome folding, but still carry the methylation signature of muscle stem cells. The reverse almost never happens. The most plausible explanation, they explained, is that these cells are caught mid-differentiation, with 3D architecture updating first and methylation catching up.
Similar mismatches appeared in Schwann cells of the peripheral nervous system and in placental trophoblasts. The pattern suggests that different epigenetic features update on different time scales during cell state transitions—a finding that could reshape how researchers define “cell type” in adult tissues and how they track cells moving between states in disease.
The atlas also revises a long-standing assumption about “non-CG methylation,” an unusual form of methylation previously thought to be largely confined to brain cells and stem cells. The study shows that it carries cell-identity information across many human tissues, including muscle, pancreas, and immune cell types, at lower but biologically meaningful levels.
“The inconsistency between modalities may be further used to determine what cell populations are switching between each other in adult tissues and diseases, which could, for example, expand our understanding of cancer cell dynamics,” said co-first and co-corresponding author Jingtian Zhou, PhD, a former graduate researcher in Ecker’s lab who now leads his own lab at the Arc Institute.
A public resource for scientists and artificial intelligence
To make the atlas broadly usable, the team built an interactive web browser that lets researchers visualize DNA methylation and 3D chromatin contacts across every tissue, cell type, and subtype in the study. The underlying data, including 195 billion methylation measurements and 18 billion chromatin contacts, are freely available.
The resource arrives as artificial intelligence tools are increasingly used to predict the functional impact of genetic variants. Atlases like this one can provide the labeled, cell-type-resolved training data that models need to make accurate predictions—a bottleneck that has historically limited the field.
For example, in a companion paper in the same issue of Science, a study led by Bing Ren, PhD, from the New York Genome Center and Columbia University used the atlas’ cross-tissue methylation data to show that a substantial fraction of the brain’s resident immune cells, called microglia, are replaced by cells resembling blood monocytes between roughly ages 50 and 75. The finding challenges the long-held view that microglia persist from embryonic development throughout the life span.
“DNA methylation patterns are specific to each cell type and analogous to a cellular barcode,” said Ren, who also co-authored the Salk-led study. “The comprehensive cross-tissue DNA methylation atlases show that the aging microglia in the human hippocampus more closely match the monocytes from peripheral blood than microglia from young adults, providing a crucial clue for the biological identity of these cells.”
The NIH 4D Nucleome consortium, of which this study is a part, aims to extend this kind of mapping into the fourth dimension: time. A 4D understanding of the genome—how its structure and chemistry change as cells develop, age, and respond to disease—remains a major goal, and the cross-tissue atlas provides reference scaffolding that future time-course studies will build on.
Along with scientists from the Salk Institute and Arc Institute, investigators from the University of California, San Diego, Columbia University, New York Genome Center, University of California, Los Angeles, Harvard, Henan University in China, Vanderbilt University, Stanford University, Broad Institute, University of Sheffield in the U.K., Yale, University of Florida, University of Freiburg in Germany, University of Graz in Austria, and Nanchang University in China; and Chongyuan Luo also contributed to the Science paper.
The post Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation appeared first on GEN – Genetic Engineering and Biotechnology News.

